Immuneering Corporation (IMRX) reported second-quarter 2026 financial results and business updates, including a net loss attributable to common stockholders of $17.3 million, or $0.27 per share, compared with $14.4 million, or $0.40 per share, a year earlier.
The company ended June 30, 2026, with $182.7 million in cash, cash equivalents and marketable securities and said its cash runway is expected to fund operations into 2029.
- R&D expenses were $14.0 million in Q2 2026, compared with $10.5 million in Q2 2025.
- G&A expenses were $5.0 million, compared with $4.3 million a year earlier.
- Immuneering reported 17.3-month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy in Phase 2a data presented at ASCO.
- The Phase 3 MAPKeeper 301 trial of atebimetinib plus mGnP in first-line metastatic pancreatic cancer is underway, with patients being dosed and more than 30 study locations posted.
- The company expects additional preclinical atebimetinib and anti-PD-1 data in Q4 2026 and MAPKeeper 301 topline data in mid-2028.
$IMRX Insider Trading Activity
$IMRX insiders have traded $IMRX stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IMRX stock by insiders over the last 6 months:
- BRETT MATTHEW HALL (CHIEF SCIENTIFIC OFFICER) purchased 6,035 shares for an estimated $25,045
- BENJAMIN J. ZESKIND (PRESIDENT AND CEO) purchased 2,400 shares for an estimated $10,948
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IMRX Hedge Fund Activity
We have seen 49 institutional investors add shares of $IMRX stock to their portfolio, and 41 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP removed 2,133,718 shares (-88.8%) from their portfolio in Q1 2026, for an estimated $11,244,693
- MARSHALL WACE, LLP added 1,284,710 shares (+180.5%) to their portfolio in Q1 2026, for an estimated $6,770,421
- MILLENNIUM MANAGEMENT LLC added 1,051,789 shares (+2065.4%) to their portfolio in Q1 2026, for an estimated $5,542,928
- BLUE OWL CAPITAL HOLDINGS LP removed 665,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $3,504,549
- LEVIN CAPITAL STRATEGIES, L.P. added 404,000 shares (+4040.0%) to their portfolio in Q2 2026, for an estimated $2,015,960
- SUMMIT FINANCIAL, LLC added 376,749 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,985,467
- CITADEL ADVISORS LLC added 356,819 shares (+394.5%) to their portfolio in Q1 2026, for an estimated $1,880,436
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
